SEARCH

SEARCH BY CITATION

References

  • 1
    Jaffe N, Carrasco H, Raymond K, Ayala A & Eftekhari F (2002) Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer 10, 22022210.
  • 2
    Benayahu D, Shur I, Meller I & Issakow J (1998) Cellular and molecular properties associated with osteosarcoma cells. J Cell Biochem 84, 108114.
  • 3
    Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, Meyers PA, Lafleur B, McDonough WS, Henry MM et al. (2005) An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 65, 17481754.
  • 4
    Grover J, Chen XN, Korenberg JR & Roughley PJ (1995) The human lumican gene. J Biol Chem 270, 2194221949.
  • 5
    Chakravarti S, Petroll WM, Hassell JR, Jester JV, Lass JH, Paul J & Birk DE (2000) Corneal opacity in lumican-null mice: defects in collagen fibril structure and packing in the posterior stroma. Invest Ophthalmol Vis Sci 41, 33653373.
  • 6
    Iozzo RV (1997) The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit Rev Biochem Mol Biol 32, 141174.
  • 7
    Ameye L & Young MF (2002) Mice deficient in small leucine-rich proteoglycans: novel in vivo models for osteoporosis, osteoarthritis, Ehlers–Danlos syndrome, muscular dystrophy, and corneal diseases. Glycobiology 12, 716.
  • 8
    Saika S, Miyamoto T, Tanaka S, Tanaka T, Ishida I, Ohnishi Y, Ooshima A, Ishiwata T, Asano G, Chikama T et al. (2003) Response of lens epithelial cells to injury: role of lumican in epithelial–mesenchymal transition. Invest Ophthalmol Vis Sci 5, 20942102.
  • 9
    Franchi A, Arganini L, Baroni G, Calzolari A, Capanna R, Campanacci D, Caldora P, Masi L, Brandi ML & Zampi G (1998) Expression of transforming growth factor beta isoforms in osteosarcoma variants: association of TGF beta 1 with high-grade osteosarcomas. J Pathol 185, 284289.
  • 10
    Naito Z (2005) The role of small leucine-rich proteoglycan (SLRP) family in pathological lesions and cancer cell growth. J Nippon Med Sch 72, 137145.
  • 11
    Kao WW (2006) Ocular surface tissue morphogenesis in normal and disease states revealed by genetically modified mice. Cornea 25(10 Suppl. 1), S7S19.
  • 12
    Funderburgh JL, Mitschler RR, Funderburgh ML, Roth MR, Chapes SK & Conrad GW (1997) Macrophage receptors for lumican. A corneal keratan sulfate proteoglycan. Invest Ophthalmol Vis Sci 38, 11591167.
  • 13
    Li Y, Aoki T, Mori Y, Ahmad M, Miyamori H, Takino T & Sato H (2004) Cleavage of lumican by membrane-type matrix metalloproteinase-1 abrogates this proteoglycan-mediated suppression of tumor cell colony formation in soft agar. Cancer Res 64, 70587064.
  • 14
    Lu YP, Ishiwata T, Kawahara K, Watanabe M, Naito Z, Moriyama Y, Sugisaki Y & Asano G (2002) Expression of lumican in human colorectal cancer cells. Pathol Int 52, 519526.
  • 15
    Naito Z, Ishiwata T, Kurban G, Teduka K, Kawamoto Y, Kawahara K & Sugisaki Y (2002) Expression and accumulation of lumican protein in uterine cervical cancer cells at the periphery of cancer nests. Int J Oncol 20, 943948.
  • 16
    Seya T, Tanaka N, Shinji S, Yokoi K, Koizumi M, Teranishi N, Yamashita K, Tajiri T, Ishiwata T & Naito Z (2006) Lumican expression in advanced colorectal cancer with nodal metastasis correlates with poor prognosis. Oncol Rep 16, 12251230.
  • 17
    Brézillon S, Venteo L, Ramont L, D’Onofrio MF, Perreau C, Pluot M, Maquart FX & Wegrowski Y (2007) Expression of lumican, a small leucine-rich proteoglycan with antitumour activity, in human malignant melanoma. Clin Exp Dermatol 32, 405416.
  • 18
    Sifaki M, Assouti M, Nikitovic D, Krasagakis K, Karamanos NK & Tzanakakis GN (2006) Lumican, a small leucine-rich proteoglycan substituted with keratan sulfate chains is expressed and secreted by human melanoma cells and not normal melanocytes. IUBMB Life 58, 606610.
  • 19
    Koninger J, Giese T, di Mola FF, Wente MN, Esposito I, Bachem MG, Giese NA, Buchler MW & Friess H (2004) Pancreatic tumor cells influence the composition of the extracellular matrix. Biochem Biophys Res Commun 322, 943949.
  • 20
    Leygue E, Snell L, Dotzlaw H, Hole K, Hiller-Hitchcock T, Roughley PJ, Watson PH & Murphy LC (1998) Expression of lumican in human breast carcinoma. Cancer Res 58, 13481352.
  • 21
    Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, Chakravarti S, Roughley PJ, Murphy LC & Watson PH (2003) Reduced expression of the small leucine-rich proteoglycans, lumican and decorin, is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res 9, 207214.
  • 22
    Vuillermoz B, Khoruzhenko A, D’Onofrio MF, Ramont L, Venteo L, Perreau C, Antonicelli F, Maquart FX & Wegrowski Y (2004) The small leucine-rich proteoglycan lumican inhibits melanoma progression. Exp Cell Res 296, 294306.
  • 23
    Yu Y, Harris RI, Yang JL, Anderson HC & Walsh WR (2004) Differential expression of osteogenic factors associated with osteoinductivity of human osteosarcoma cell lines. J Biomed Mater Res A 70, 122128.
  • 24
    Hanaoka E, Ozaki T, Nakamura Y, Moriya H, Nakagawara A & Sakiyama S (2000) Overexpression of DAN causes a growth suppression in p53-deficient SAOS-2 cells. Biochem Biophys Res Commun 278, 2026.
  • 25
    Vij N, Roberts L, Joyce S & Chakravarti S (2004) Lumican suppresses cell proliferation and aids Fas–Fas ligand mediated apoptosis: implications in the cornea. Exp Eye Res 78, 957971.
  • 26
    Saika S, Shiraishi A, Liu CY, Funderburgh JL, Kao CW, Converse RL & Kao WW (2000) Role of lumican in the corneal epithelium during wound healing. J Biol Chem 275, 26072612.
  • 27
    Jukkola A, Risteli L, Melkko J & Risteli J (1993) Procollagen synthesis and extracellular matrix deposition in MG-63 osteosarcoma cells. J Bone Miner Res 8, 651657.
  • 28
    Rahimi RA & Leof EB (2007) TGF-beta signaling: a tale of two responses. J Cell Biochem 102, 593608.
  • 29
    Herpin A & Cunningham C (2007) Cross-talk between the bone morphogenetic protein pathway and other major signaling pathways results in tightly regulated cell-specific outcomes. FEBS J 274, 29772985.
  • 30
    Taichman RS, Reilly MJ & Emerson SG (1994) Human osteosarcomas inhibit hematopoietic colony formation: partial reversal by antibody to transforming growth factor-beta 1. Bone 21, 353361.
  • 31
    Funderburgh JL, Funderburgh ML, Mann MM, Corpuz L & Roth MR (2001) Proteoglycan expression during transforming growth factor beta-induced keratocyte–myofibroblast transdifferentiation. J Biol Chem 276, 4417344178.
  • 32
    Hao J, Ju H, Zhao S, Junaid A, Scammell-La Fleur T & Dixon IM (1999) Elevation of expression of Smads 2, 3, and 4, decorin and TGF-beta in the chronic phase of myocardial infarct scar healing. J Mol Cell Cardiol 31, 667678.
  • 33
    Cabello-Verrugio C & Brandan E (2007) A novel modulatory mechanism of transforming growth factor-beta signaling through decorin and LRP-1. J Biol Chem 282, 1884218850.
  • 34
    Lallier TE, Spencer A & Fowler MM (2005) Transcript profiling of periodontal fibroblasts and osteoblasts. J Periodontol 76, 10441055.
  • 35
    Raouf A, Ganss B, McMahon C, Vary C, Roughley PJ & Seth A (2002) Lumican is a major proteoglycan component of the bone matrix. Matrix Biol 21, 361367.
  • 36
    Hood JD & Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2, 91100.
  • 37
    Vihinen P, Riikonen T, Laine A & Heino J (1996) Integrin α1β1 in tumorigenic human osteosarcoma cell lines regulates cell adhesion, migration, and invasion by interaction with type I collagen. Cell Growth Differ 7, 439447.
  • 38
    Nesti LJ, Caterson EJ, Wang M, Chang R, Chapovsky F, Hoek JB & Yuan RS (2002) TGF-beta1 calcium signalling increases alpha5 integrin expression in osteoblasts. J Orthop Res 20, 10421049.
  • 39
    Lai CF, Feng X, Nishimura R, Teitelbaum SL, Avioli LV, Ross FP & Cheng SL (2000) Transforming growth factor-beta up-regulates the beta 5 integrin subunit expression via Sp1 and Smad signalling. J Biol Chem 275, 3640036406.
  • 40
    Moursi AM, Globus RK & Damsky CH (1997) Interactions between integrin receptors and between integrin receptors and fibronectin are required for calvarial osteoblast differentiation in vitro. J Cell Sci 110, 21872196.
  • 41
    Moursi AM, Damsky CH, Lull J, Zimmerman D, Doty SB, Aota S & Globus RK (1996) Fibronectin regulates calvarial osteoblast differentiation. J Cell Sci 109, 13691380.